Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Olga Bragina; Vladimir Chernov; Alexey Schulga; Elena Konovalova; Eugeniy Garbukov; Anzhelika Vorobyeva; Anna Orlova; Liubov Tashireva; Jens Sörensen; Roman Zelchan; Anna Medvedeva; Sergey Deyev; Vladimir Tolmachev

doi:10.2967/jnumed.121.262542

Research ArticleClinical (Molecular Imaging: Peptides)

Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Olga Bragina, Vladimir Chernov, Alexey Schulga, Elena Konovalova, Eugeniy Garbukov, Anzhelika Vorobyeva, Anna Orlova, Liubov Tashireva, Jens Sörensen, Roman Zelchan, Anna Medvedeva, Sergey Deyev and Vladimir Tolmachev

Journal of Nuclear Medicine April 2022, 63 (4) 528-535; DOI: https://doi.org/10.2967/jnumed.121.262542

Olga Bragina

1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia;

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vladimir Chernov

1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia;

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alexey Schulga

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

3Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elena Konovalova

3Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eugeniy Garbukov

4Department of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center Russian Academy of Sciences, Tomsk, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anzhelika Vorobyeva

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

5Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anna Orlova

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

6Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Liubov Tashireva

7Department of General and Molecular Pathology, Tomsk National Research Medical Center, Tomsk, Russia; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jens Sörensen

8Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Roman Zelchan

1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia;

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anna Medvedeva

1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sergey Deyev

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

3Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vladimir Tolmachev

2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

5Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 63, Issue 4

April 1, 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Journal of Nuclear Medicine Apr 2022, 63 (4) 528-535; DOI: 10.2967/jnumed.121.262542

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Journal of Nuclear Medicine Apr 2022, 63 (4) 528-535; DOI: 10.2967/jnumed.121.262542

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Designed Ankyrin Repeat Proteins for detecting prostate-specific antigen expression in vivo

Google Scholar

Keywords

HER2
DARPin G3
99mTc
SPECT
phase I

Main menu

User menu

Search

Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

Similar Articles

Keywords